Related Experiment Video
Updated: Jul 5, 2026

Local Anesthetic Thoracoscopy for Undiagnosed Pleural Effusion
Published on: November 10, 2023
Refractory hypercalcemia in an infant secondary to talc pleurodesis resolving after renal transplantation
S J Aujla1, P Michelson, C B Langman
1Division of Pulmonary Medicine, Allergy and Immunology, Department of Pediatrics, Children's Hospital of Pittsburgh, The University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
Insights
Talc pleurodesis can cause severe hypercalcemia due to extrarenal 1,25-dihydroxyvitamin D production. Alemtuzumab treatment following renal transplantation resolved this complication in an infant.
Area of Science:
- Nephrology
- Endocrinology
- Immunology
Background:
- Talc pleurodesis is standard for recurrent pneumothorax, typically without metabolic issues.
- Recurrent peritoneal dialysis-related hydrothorax necessitates interventions like talc pleurodesis.
Observation:
- An anephric infant developed severe hypercalcemia six months post-talc pleurodesis.
- Elevated 1,25-dihydroxyvitamin D (1,25[OH]2D) levels, from macrophage-derived extrarenal production in a talc granuloma, caused the hypercalcemia.
Findings:
- Hypercalcemia was managed with diet, dialysis, ketoconazole, and hydroxychloroquine, but 1,25[OH]2D remained high.
- Renal transplantation with alemtuzumab pre-conditioning resolved hypercalcemia and normalized 1,25[OH]2D levels.
Implications:
- Talc pleurodesis can lead to hypercalcemia via extrarenal 1,25(OH)2D production.
- Alemtuzumab, targeting macrophages, may treat hypercalcemia in granulomatous conditions.
Abstract:
Talc pleurodesis is the definitive therapy of recurrent pneumothorax and has not been associated with metabolic complications. We report an anephric male infant who developed severe hypercalcemia 6 months following talc pleurodesis for recurrent peritoneal dialysis-related hydrothorax. The etiology of hypercalcemia was related to persistently elevated 1,25-dihydroxyvitamin D(3) (1,25[OH]2D) levels. The source appeared to be the extrarenal production of 1,25(OH)2D from macrophages in a large thoracic talc granuloma. Hypercalcemia was controlled with a combination of a low calcium diet, low calcium dialysis, ketoconazole and hydroxychloroquine, but elevated 1,25(OH)2D levels persisted. At 32 months of age the child underwent renal transplantation with alemtuzumab pre-conditioning. The hypercalcemia resolved immediately, with normalization of serum 1,25(OH)2D levels and without hypercalciuria. This case demonstrates that hypercalcemia is a potential complication of talc pleurodesis from the extrarenal production of 1,25(OH)2D and that alemtuzumab, a monoclonal antibody directed against the CD52 antigen (which is expressed on almost all macrophages), may have a role in the treatment of hypercalcemia associated with granulomatous conditions.
Related Concept Videos
Kidney Transplant II: Surgical Procedure
Pneumothorax-II
Clinical Manifestations:
Urinary Tract Calculi IV: Nutrition Therapy and Prevention
Urinary Tract Calculi V: Nursing Management
Kidney Transplant III: Nursing Management
Urinary Tract Calculi III: Medical Management